Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Complete Title: A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Trial Phase: I/II
Investigator: Katherine Tarlock
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
Keywords:
- Endometrial Cancer; Melanoma; Neuroblastoma; Lymphoma, Non-Hodgkin (NHL); Ovarian Cancer; Sarcoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Fibromatosis, Aggressive; Hepatoblastoma; Solid Tumors; Wilms' Tumor; Neoplasms; Sarcoma, Ewing; Osteosarcoma; Adenocarcinoma
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.